Literature DB >> 32013309

Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.

S K Kritas1, G Ronconi2, Al Caraffa3, C E Gallenga4, R Ross5, P Conti6.   

Abstract

Coronavirus can cause respiratory syndrome which to date has affected about twelve thousand individuals, especially in China. Coronavirus is interspecies and can also be transmitted from man to man, with an incubation ranging from 1 to 14 days. Human coronavirus infections can induce not only mild to severe respiratory diseases, but also inflammation, high fever, cough, acute respiratory tract infection and dysfunction of internal organs that may lead to death. Coronavirus infection (regardless of the various types of corona virus) is primarily attacked by immune cells including mast cells (MCs), which are located in the submucosa of the respiratory tract and in the nasal cavity and represent a barrier of protection against microorganisms. Viral activate MCs release early inflammatory chemical copounds including histamine and protease; while late activation provoke the generation of pro-inflammatory IL-1 family members including IL-1, IL-6 and IL-33. Here, we propose for the first time that inflammation by coronavirus maybe inhibited by anti-inflammatory cytokines belonging to the IL-1 family members. Copyright 2019 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  Coronavirus; immunity; infection; inflammation; mast cell

Year:  2020        PMID: 32013309     DOI: 10.23812/20-Editorial-Kritas

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  77 in total

Review 1.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

Review 2.  Coronavirus Disease 2019-COVID-19.

Authors:  Kuldeep Dhama; Sharun Khan; Ruchi Tiwari; Shubhankar Sircar; Sudipta Bhat; Yashpal Singh Malik; Karam Pal Singh; Wanpen Chaicumpa; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales
Journal:  Clin Microbiol Rev       Date:  2020-06-24       Impact factor: 26.132

Review 3.  Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection.

Authors:  Valentina Ruggiero; Rita P Aquino; Pasquale Del Gaudio; Pietro Campiglia; Paola Russo
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

4.  Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications.

Authors:  Loredana Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

Review 5.  Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices.

Authors:  Matthew A Sparks; Andrew M South; Andrew D Badley; Carissa M Baker-Smith; Daniel Batlle; Biykem Bozkurt; Roberto Cattaneo; Steven D Crowley; Louis J Dell'Italia; Andria L Ford; Kathy Griendling; Susan B Gurley; Scott E Kasner; Joseph A Murray; Karl A Nath; Marc A Pfeffer; Janani Rangaswami; W Robert Taylor; Vesna D Garovic
Journal:  Hypertension       Date:  2020-09-28       Impact factor: 10.190

6.  Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.

Authors:  Chenyu Sun; Yue Chen; Lei Hu; Yile Wu; Mingming Liang; Mubashir Ayaz Ahmed; Chandur Bhan; Zhichun Guo; Hongru Yang; Yijing Zuo; Yue Yan; Qin Zhou
Journal:  Dig Dis Sci       Date:  2021-02-24       Impact factor: 3.199

Review 7.  Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis.

Authors:  Rajesh Swarnakar; Yogesh Garje; Neeraj Markandeywar; Suyog Mehta
Journal:  Lung India       Date:  2022 May-Jun

8.  Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019.

Authors:  Saravanan Subramaniam; Wolfram Ruf; Markus Bosmann
Journal:  Br J Pharmacol       Date:  2021-07-07       Impact factor: 8.739

Review 9.  Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

Authors:  Changbo Qu; Gwenny M Fuhler; Yihang Pan
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?

Authors:  Hashim Islam; Thomas C Chamberlain; Alice L Mui; Jonathan P Little
Journal:  Front Immunol       Date:  2021-06-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.